Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Preferred Dividend Payments for 4 consecutive years, with $2.6 million as the latest value for Q2 2025.

  • For Q2 2025, Preferred Dividend Payments fell 37.55% year-over-year to $2.6 million; the TTM value through Jun 2025 reached $6.8 million, up 62.45%, while the annual FY2016 figure was $4.6 million, 37.75% down from the prior year.
  • Preferred Dividend Payments hit $2.6 million in Q2 2025 for Cartesian Therapeutics, down from $4.2 million in the prior quarter.
  • Across five years, Preferred Dividend Payments topped out at $4.2 million in Q2 2024 and bottomed at $2.6 million in Q2 2025.